Severe Acute Pancreatitis Complicated by Guillain-Barré Syndrome in the Intensive Care Unit Authors: Dan Wang, Xianlin Meng, Tingting Ye, Chunyan Zhu Published: 2026 ABSTRACT ABSTRACTSevere acute pancreatitis (SAP) rarely causes immune-mediated neurological complications. We report Guillain-Barré syndrome (GBS), acute motor and sensory axonal neuropathy subtype, occurring during SAP requiring extracorporeal membrane oxygenation and continuous renal replacement therapy. A 39-year-old woman with hyperlipidemic pancreatitis and autoimmune diseases developed abrupt symmetric flaccid quadriplegia after sedation withdrawal in the intensive care unit. Electrophysiological studies and cerebrospinal fluid analysis confirmed the diagnosis of GBS. Intravenous immunoglobulin therapy resulted in gradual neurological improvement. This case highlights the diagnostic challenge of recognizing GBS in critically ill patients with SAP. Clinicians should suspect GBS when unexplained symmetric weakness occurs after sedation withdrawal and perform early electrophysiological evaluation with prompt immunomodulatory therapy. INTRODUCTION Severe acute pancreatitis (SAP) is a critical inflammatory condition frequently complicated by systemic inflammatory response syndrome and multiple organ dysfunction.1,2 Although infectious, coagulation, and metabolic complications are common,3 immune-mediated neurological complications are rare. We report a patient who developed acute quadriplegia during the course of SAP and was ultimately diagnosed with Guillain-Barré syndrome (GBS), acute motor and sensory axonal neuropathy (AMSAN) subtype, highlighting the need to consider this uncommon but serious complication in critically ill patients with SAP. CASE REPORT A 39-year-old woman with type 2 diabetes mellitus, Hashimoto's thyroiditis, Sjögren syndrome, and hyperlipidemia was admitted to the intensive care unit (ICU) with severe hyperlipidemic acute pancreatitis. Two days before admission, she developed sudden severe epigastric pain with nausea and vomiting after a heavy meal. Laboratory testing showed markedly elevated amylase (692 U/L), lipase (1397 U/L), triglycerides (44.6 mmol/L), and metabolic acidosis. Abdominal computed tomography confirmed SAP. The patient's overall clinical timeline during the ICU course is shown in Figure 1. Clinical timeline of the patient during the intensive care unit course, including admission with severe acute pancreatitis, initiation of ECMO, withdrawal of sedation, development of Guillain-Barré syndrome, administration of intravenous immunoglobulin therapy, and neurological recovery. ECMO, extracorporeal membrane oxygenation; MRC, Medical Research Council. On ICU admission (day 1), she was in shock with hypoxemic respiratory failure (heart rate 132 beats/min, blood pressure 89/55 mm Hg, oxygen saturation 88% on supplemental oxygen). Physical examination revealed lethargy, bilateral pulmonary rales, abdominal distension with tenderness, decreased bowel sounds, and cold extremities with prolonged capillary refill. Laboratory evaluation demonstrated markedly elevated inflammatory markers, hepatic and renal dysfunction, oliguria, and severe thrombocytopenia (16 × 109/L), consistent with SAP-associated multiple organ dysfunction. Nasopharyngeal swab testing was positive for influenza A virus, and sputum culture grew Aspergillus fumigatus. Immunologic testing revealed positive antinuclear and anti-SSA antibodies. Chest computed tomography demonstrated acute respiratory distress syndrome (Figure 2), whereas cranial imaging was unremarkable. Chest and abdominal CT results. (A) and (B) Axial chest CT images show bilateral pulmonary infiltrates with ground-glass opacities and patchy consolidation, consistent with the features of acute respiratory distress syndrome. (C) and (D) Abdominal CT shows diffuse pancreatic enlargement with significant peripancreatic inflammation and fluid accumulation (indicated by the red box), suggesting severe acute pancreatitis. CT, computed tomography. The patient received supportive management for SAP-related multiple organ dysfunction, including vasopressor therapy, mechanical ventilation, continuous renal replacement therapy, and antimicrobial treatment. Veno-venous extracorporeal membrane oxygenation was initiated on ICU day 4 for refractory hypoxemia and discontinued on day 19. On ICU day 22, after withdrawal of sedation, the patient developed abrupt symmetric flaccid quadriplegia (Medical Research Council grade 0 in all limbs) with absent tendon reflexes and preserved sensation. Cranial nerve examination was normal. Nerve conduction studies demonstrated reduced compound muscle action potential and sensory nerve action potential amplitudes with prolonged F-waves and H-reflexes, consistent with the AMSAN subtype of GBS. Cerebrospinal fluid analysis revealed elevated protein (1.17 g/L) with pleocytosis, evolving toward albuminocytologic dissociation on repeat examination. Intravenous immunoglobulin therapy (30 g/day for 5 days) was initiated, followed by gradual neurological improvement. Neurological recovery after intravenous immunoglobulin therapy is summarized in Table 1. Table 1.Recovery of limb muscle strength assessed by the Medical Research Council scale after intravenous immunoglobulin therapyTimeDay 1Day 2Day 3Day 4Day5Day6Upper limb muscle strength011234Lower limb muscle strength011112 Recovery of limb muscle strength assessed by the Medical Research Council scale after intravenous immunoglobulin therapy DISCUSSION GBS is an immune-mediated acute peripheral neuropathy characterized by rapidly progressive, symmetric flaccid paralysis with hyporeflexia or areflexia.4,5 It is typically triggered by infections or systemic inflammatory states and may involve demyelinating or axonal injury. Although often self-limiting, delayed recognition can lead to substantial morbidity. The reported incidence of GBS among ICU patients is ∼0.3%–0.5%, and its occurrence in association with noninfectious conditions such as SAP is exceedingly rare.6 SAP is commonly complicated by systemic inflammation and multiple organ dysfunction, which may obscure neurological manifestations, particularly in sedated and mechanically ventilated patients.7 This case underscores the diagnostic challenge of recognizing GBS after sedation withdrawal in critically ill patients with SAP. Although a direct causal relationship between SAP and GBS has not been established, several factors may contribute. SAP induces profound systemic inflammation and immune dysregulation, which may facilitate immune-mediated nerve injury.8–10 Antecedent infections are recognized triggers of GBS.11 In this case, concomitant influenza A virus infection may have contributed through immune activation and molecular mimicry.12 In addition, underlying autoimmune diseases suggest baseline immune susceptibility, potentially lowering the threshold for autoimmune neuropathy during systemic inflammatory stress. After sedation withdrawal, the abrupt onset of symmetric flaccid quadriplegia with areflexia prompted consideration of GBS. ICU-acquired weakness was the primary differential diagnosis; however, several features favored GBS, including rapid monophasic progression, evolution toward albuminocytologic dissociation on serial cerebrospinal fluid examinations, axonal changes on electrophysiological studies, and clinical improvement after intravenous immunoglobulin therapy, which is ineffective in ICU-acquired weakness.13 Central nervous system, metabolic, and drug-induced causes were excluded based on neuroimaging, laboratory evaluation, and clinical findings. According to the Brighton criteria, this case meets level 2 diagnostic certainty for GBS, supported by symmetric flaccid weakness with areflexia, a monophasic disease course, supportive electrophysiological findings, and cerebrospinal fluid evolution.13 The electrophysiological pattern was consistent with the AMSAN subtype, which is associated with more severe axonal injury and slower recovery than demyelinating forms. Prompt initiation of intravenous immunoglobulin resulted in gradual neurological improvement. Although full recovery was not achieved, the patient overcame the critical phase, and prolonged rehabilitation is anticipated. In conclusion, GBS should be considered in patients with SAP who develop abrupt symmetric flaccid weakness after sedation withdrawal, particularly in the absence of central nervous system pathology. Early neurological assessment, electrophysiological testing, and timely immunomodulatory therapy are essential to improve outcomes in this rare but serious complication. DISCLOSURES Author contributions: C. Zhu is responsible for the article's content, data accuracy, ethical compliance of the research, and the contributions of all authors, ensuring that the manuscript meets the ethical and legal requirements for academic publication. C. Zhu is the article guarantor. D. Wang made key contributions to the conception and design of the article, data collection, and analysis. X. Meng provided important support in clinical data analysis and case description design. T. Ye is responsible for data collection and organization and participates in literature search and data integration. Financial disclosure: None to report. Informed consent was obtained for this case report.